A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Inovio Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: February 16, 2011
Last updated: March 23, 2015
Last verified: March 2015